The primary objective of this review is to provide a high-level, retrospective analysis of the JAK-STAT signaling axis, marking three decades since its initial discovery. It aims to chart the pathway’s conceptual evolution—from a primary mediator of interferon (IFN)-induced antiviral responses to a sophisticated, multi-layered regulatory hub essential for human physiology. By synthesizing contemporary research, the review seeks to establish a modern "knowledge map" that clarifies how extracellular signals are translated into diverse cellular outcomes, including immune homeostasis, metabolic regulation, and developmental programming, thereby providing a theoretical scaffold for next-generation therapeutic interventions.

This review employs a multi-disciplinary approach to dissect the JAK-STAT pathway. It integrates structural biology to analyze the unique domain architecture of JAK kinases and STAT proteins, and functional genomics to explore the pathway’s expanded role in epigenetic regulation, including chromatin remodeling and super-enhancer activation. The analysis incorporates a comparative genetic review of loss-of-function (LOF) and gain-of-function (GOF) mutations identified in both murine models and human clinical cohorts. Furthermore, the review utilizes Rheumatoid Arthritis (RA) as a primary pathological case study, systematically deconstructing the molecular mechanisms—such as Th17/Treg imbalance and synovial fibroblast activation—that link pathway dysregulation to chronic autoimmunity and joint destruction.

The findings highlight the dual nature of the JAK-STAT axis as both a linear signaling cascade and a complex regulatory network.

Structural Insights: We delineate the critical role of the JAK pseudokinase domain in regulating catalytic activity and the functional specialization of the seven STAT family members.

Beyond the Nucleus: The review identifies significant "non-canonical" roles for STAT proteins, particularly their influence on mitochondrial bioenergetics and their capacity to modulate the non-coding RNA landscape.

Clinical Pathologies: Genetic analysis reveals that JAK-STAT mutations are direct drivers of a broad spectrum of diseases, from primary immunodeficiencies (SCID) to systemic interferonopathies and myeloproliferative neoplasms.

RA Pathogenesis: Within the RA microenvironment, the pathway is revealed as the central engine driving the "tumor-like" behavior of fibroblast-like synoviocytes (FLS) and the upregulation of matrix metalloproteinases (MMPs), which directly results in irreversible bone erosion and cartilage loss.

The review concludes that while the first generation of JAK inhibitors has revolutionized the treatment of inflammatory diseases, significant challenges regarding selectivity and side effects remain. The future of the field lies in the transition toward "Precision JAK-STAT Targeting." This involves the development of isoform-specific inhibitors, allosteric modulators that target the pseudokinase domain, and the application of PROTAC technology for targeted protein degradation. By leveraging emerging data from single-cell multi-omics and systems biology, clinicians and researchers can develop more refined intervention strategies, moving beyond broad immunosuppression toward targeted, patient-specific modulation of the JAK-STAT axis.